On the chart you can see the default numbers in dynamics for Marksans Pharma Limited (MARKSANS.NS). Companys revenue shows the average of 7206.416 M which is 0.110 % gowth. The average gross profit for the whole period is 3092.738 M which is 0.151 %. The average gross profit ratio is 0.365 %. The net income growth for the company last year performance is 0.443 % which equals -0.591 % % on average for the whole company history.,
Diving into the fiscal trajectory of Marksans Pharma Limited, we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to . A look back at the past year reveals a total asset change of 0.336. In the realm of current assets, MARKSANS.NS clocks in at 16753.01 in the reporting currency. A significant portion of these assets, precisely 7191.57, is held in cash and short-term investments. This segment shows a change of 1.074% when juxtaposed with last year's data. The debt profile of the company shows a total long-term debt of 656.89 in the reporting currency. This figure signifies a year_over_year change of 0.110%. Shareholder value, as depicted by the total shareholder equity, is valued at 17451.62 in the reporting currency. The year over year change in this aspect is 0.452%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 4187.62, with an inventory valuation of 4847.39, and goodwill valued at 384.89, if any. The total intangible assets, if present, are valued at 707.97.
The financial landscape of Marksans Pharma Limited has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of 2.472. The company recently extended its share capital by issuing 2747.09, marking a difference of 10.713 compared to the previous year. The company's investing activities resulted in net cash usage, amounting to -2592120000.000 in the reporting currency. This is a shift of 5.218 from the previous year. In the same period, the company recorded 518.53, -2055.81, and -2295.43, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated -101.71 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 2080, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.
Marksans Pharma Limited's revenue saw a change of 0.251% compared with the previous period. The gross profit of MARKSANS.NS is reported to be 9307.81. The company's operating expenses are 6433.13, showing a change of 24.825% from the last year. The expenses for depreciation and amortization are 518.53, which is a 0.158% change from the last accounting period. Operating expenses are reported to be 6433.13, which shows a 24.825% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a 0.344% year-over-year growth. The operating income is 2877.32, which shows a 0.344% change when compared to the previous year. The change in the net income is 0.443%. The net income for the last year was 2663.08.
